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Abstract 24 
We previously demonstrated that the C-terminus of the capsid gene of porcine circovirus type 2 25 
(PCV2) is an immune reactive epitope displayed on the surface of virions. Insertion of foreign 26 
epitope tags in the C-terminus produced infectious virions that elicited humoral immune 27 
responses against both PCV2 capsid and the inserted epitope tags, whereas mutation in the N 28 
terminus impaired viral replication. Since the non-pathogenic porcine circovirus type 1 (PCV1) 29 
shares similar genomic organization and significant sequence identity with pathogenic PCV2, in 30 
this study we evaluated whether PCV1 can serve as a vaccine delivery virus vector. Four 31 
different antigenic determinants of porcine reproductive and respiratory syndrome virus 32 
(PRRSV) were inserted in the C-terminus of the PCV1 capsid gene, the infectivity and 33 
immunogenicity of the resulting viruses are determined. We showed that an insertion of 12 34 
(PRRSV-GP2 epitope II, PRRSV-GP3 epitope I, and PRRSV-GP5 epitope I), and 14 (PRRSV-35 
GP5 epitope IV) amino acid residues did not affect PCV1 replication. We successfully rescued 36 
and characterized four chimeric PCV1 viruses expressing PRRSV linear antigenic determinants 37 
(GP2 epitope II: aa 40–51, ASPSHVGWWSFA; GP3 epitope I: aa 61–72, QAAAEAYEPGRS; 38 
GP5 epitope I: aa 35–46, SSSNLQLIYNLT; and GP5 epitope IV: aa 187–200, 39 
TPVTRVSAEQWGRP). We demonstrated that all chimeric viruses were stable and infectious in 40 
vitro and three chimeric viruses were infectious in vivo. An immunogenicity study in pigs 41 
revealed that PCV1-VR2385EPI chimeric viruses elicited neutralizing antibodies against PRRSV-42 
VR2385. The results have important implications for further evaluating PCV1 as a potential 43 
vaccine delivery vector. 44 
Keywords: Vaccine delivery vector; Porcine circovirus type 1 (PCV1); Porcine reproductive and 45 
respiratory syndrome virus (PRRSV); Antigenic epitopes; Porcine circovirus type 2 (PCV2)   46 
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1. Introduction 47 
Porcine circoviruses (PCV) belong to the genus Circovirus of the family Circoviridae 48 
(Finsterbusch and Mankertz, 2009). The viral genome is packaged in an icosahedral capsid 49 
approximately 17 nm in diameter, and PCV is the smallest virus infecting mammals. Two types 50 
of PCV, PCV1 and PCV2, have been identified thus far. PCV1 was first described in 1974 as a 51 
contaminant of the porcine kidney cell line, PK-15, and is non-pathogenic in pigs (Tischer et al., 52 
1982). PCV2 is pathogenic and causes an economically-important porcine circovirus-associated 53 
diseases (PCVAD) in swine worldwide (Allan et al., 1998; Allan et al., 1999; Ellis et al., 1998).  54 
Both PCV1 and PCV2 are non-enveloped, single-stranded circular DNA molecules of 1,759 55 
(PCV1) and 1,768 (PCV2) kb in size (Finsterbusch and Mankertz, 2009).  56 
The non-pathogenic PCV1 shares similar genomic organization with the PCVAD-57 
associated PCV2 (Chae, 2005), which is characterized by 11 potential open reading frames 58 
(ORFs) with predicted protein sizes ranging from 2 to 36 kDa (Hamel et al., 1998). However, 59 
thus far only two major ORFs are believed to be essential for completing the basic functions of 60 
the virus: ORF1 encodes the replicase (Rep) (314 aa) and the truncated, spliced Rep’ (178 aa), 61 
whereas the ORF2 encodes the immunogenic capsid protein (233 aa). Sequence analyses 62 
revealed that PCV1 shares a 76% nucleotide sequence identity with its pathogenic counterpart 63 
PCV2. The ORF1-encoded replicase protein has approximately 80% amino acid sequence 64 
identity between the two viruses, whereas the ORF2 capsid protein has about 60% amino acid 65 
sequence identity (Mahé et al., 2000; Trible and Rowland, 2012). The ORF1 and ORF2 genes 66 
are oriented in opposite directions, resulting in an ambisense orientation. Between the 5’ end of 67 
ORF1 and ORF2, there exists an intergenic region that contains the origin of virus replication 68 
characterized by a stem-loop structure (Mankertz et al., 2004).  69 
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Since the initial identification of PCV2 (Ellis et al., 1998), several genotypes have now 70 
been described (Jantafong et al., 2011; Wang et al., 2009) and demonstrated to co-exist in pigs 71 
(Allan et al., 2012; Zhai et al., 2011). For a single-stranded DNA virus, PCV2 has been shown to 72 
have the highest DNA mutation rate that is comparable to single-stranded RNA viruses (Firth et 73 
al., 2009). In contrast, the non-pathogenic PCV1 has been demonstrated to have a low mutation 74 
rate and low genetic diversity worldwide (Cortey and Segalés, 2012; Tombácz et al., 2014). 75 
While PCV2 is highly prevalent in most swine-producing countries and is associated with 76 
clinical PCVAD, PCV1 is non-pathogenic and has a low prevalence in swine herds (Allan et al., 77 
1994; Allan et al., 1995; Calsamiglia et al., 2002; Dulac and Afshar, 1989; Edwards and Sands, 78 
1994; Kim and Chae, 2001; Krakowka et al., 2000; Magar et al., 2000; Tischer et al., 1986). A 79 
recent survey demonstrated that, while PCV2 DNA and PCV2-specific antibodies are present in 80 
more than 80% of the samples evaluated, the molecular and serological prevalence of PCV1 is 81 
less than 2.4% (Puvanendiran et al., 2011).  82 
We previously demonstrated that a genetically modified infectious PCV2 can tolerate up 83 
to a 27 aa insertion in the C-terminus of the ORF2 capsid gene (Beach et al., 2011). We showed 84 
that insertion of single, dimeric, and trimeric hemagglutinin (HA) tags, a GLu-GLu epitope tag 85 
of a mouse polyomavirus, and the KT3 epitope tag of the simian virus 40 in the C-terminus of 86 
PCV2 capsid gene resulted in infectious chimeric viruses that induce both PCV2-neutralizing 87 
antibodies and anti-epitope tag antibodies (Beach et al., 2011). Another study reported that 88 
insertion of a VP1 epitope region (aa 141–160, LTNVRGDLQVLAQKAARPLP) of the foot and 89 
mouth disease virus (FMDV) in PCV2 produced infectious virus in vitro and in a mouse model, 90 
and the PCV2-FMDV chimera elicited dual immunity against PCV2 and FMDV (Huang et al., 91 
2014). We recently demonstrated that chimeric PCV1-2a vaccine can tolerate the insertion of 92 
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linear PRRSV epitope and induce dual immunity again PCV2 and PRRSV as a potential bivalent 93 
vaccine (Pineyro et al., 2015)  94 
Because of the low prevalence of PCV1 in swine herds, the non-pathogenic nature, the 95 
low mutation rate, and the systemic tropisms of PCV1 for multiple tissues and organs, it is 96 
logical to explore the potential use of PCV1 as a vaccine delivery virus vector. Therefore, in this 97 
study, as a proof-of-principle, we evaluated whether PCV1 can express known antigenic 98 
determinants of porcine reproductive and respiratory syndrome virus (PRRSV), an 99 
economically-important swine pathogen. Generation of chimeric viruses containing neutralizing 100 
antigenic epitopes of PRRSV in the backbone of the non-pathogenic PCV1 could potentially 101 
elicit protective immunity against PRRSV with the benefit of a live virus-vectored vaccine, but 102 
without the risk of pathogenicity or reversion to virulence often associated with the traditional 103 
modified live-attenuated vaccines. 104 
 105 
2. Materials and methods  106 
2.1. Construction of chimeric PCV1-PRRSVEPI (epitope) infectious clones: 107 
Four different known antigenic epitopes derived from PRRSV strain VR2385, including 108 
GP2 epitope II (aa 40–51, ASPSHVGWWSFA), GP3 epitope I (aa 61–72, QAAAEAYEPGRS), 109 
GP5 epitope I (aa 35–46, SSSNLQLIYNLT), and GP5 epitope IV (aa 187–200, 110 
TPVTRVSAEQWGRP), were each cloned individually in frame into the C-terminus of the 111 
PCV1 capsid gene (GenBank accession number GU799575). Chimeric viruses were constructed 112 
by overlapping extension and fusion PCR following a method previously described (Beach et al., 113 
2011). Briefly, a pCR2.1-PCV1 infectious clone plasmid containing the full-length PCV1 114 
genome was used as the template to generate two amplicons of 200 bp and 1,800 bp with 115 
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complementary overhangs containing individual PRRSV antigenic epitope sequences (Table 1). 116 
A second round of fusion PCR was performed to assemble the previously synthesized amplicons. 117 
The PCR product was digested with KpnI and inserted into the pCR2.1TOPO vector (Invitrogen) 118 
(Fig. 1). Recombinant plasmids containing the insert were transformed into the alpha-select 119 
strain of E. coli (Bioline). Positive clones were selected, and insertion of each specific PRRSV 120 
epitope was confirmed by DNA sequencing. The viral genomic DNA was excised from the 121 
plasmid by enzymatic digestion with KpnI and concatemerization was carried out through a 122 
ligation reaction with T4 DNA ligase (Invitrogen), overnight, at room temperature. The 123 
infectious chimeric virus was generated by transfection of the concatemerized genomic DNA 124 
into the PCV1-free PK15 cells at 30%–40% confluency with lipofectamine ltx (Invitrogen). 125 
After 72 h post-transfection, the infectious virus was harvested by three cycles of freezing and 126 
thawing of the cells.  127 
 128 
2.2. In vitro infectivity, epitope expression, and titration of chimeric PCV1-PRRSVEPI 129 
viruses: 130 
PCV1-free PK-15 cells were seeded at a concentration of 2 × 105 cells/well in a 48-well 131 
plate. After reaching approximately 40%–50% confluency, cells were washed once with Hank’s 132 
Balanced Salt Solution (Gibco). The cells were then incubated with 100 µL of 1:10 serial 133 
dilution of the virus stock for 1 h at 37°C in 5% CO2, after which the cells were washed once 134 
with 200 µL of minimum essential media (MEM) (Gibco). Infection was carried out in 300 µL 135 
MEM supplemented with 10% FBS (Invitrogen) and 1% antibiotic/antimycotic (Fisher) at 37°C 136 
in 5% CO2. After 72 h post-infection, the cells were fixed with 80% acetone and the infectivity 137 
was assessed by an immunofluorescence assay (IFA).  138 
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Briefly, infected cells were incubated with 100 µL of mouse anti-PCV1-Cap monoclonal 139 
antibody, followed by fluorescein isothiocyanate-conjugated goat anti-mouse IgG (KPL, 140 
Kirkegaard & Perry Laboratories, Inc.). Expression of PRRSV-specific antigenic epitopes was 141 
also confirmed by IFA using custom polyclonal rabbit antibodies (Biomatik) against each 142 
synthetic PRRSV epitope followed by secondary goat anti-rabbit IgG (DyLight 550). Cells 143 
positive for both PCV1 Cap and PRRSV epitopes were visualized using a Zeiss LSM 880 144 
confocal microscope (Zeiss, Pleasanton, CA). Serial ten-fold dilutions of the virus stock were 145 
performed in order to determine the 50% tissue culture infectious dose (TCID50) of the virus 146 
stocks according to the method described by of Reed and Muench (Reed and Muench, 1938).  147 
 148 
2.3. In vivo characterization of the infectivity and immunogenicity of four PCV1-149 
PRRSVEPI chimeric viruses  150 
2.3.1. Experimental design for the animal study  151 
A total of 21 5-weeks-old specific-pathogen-free (SPF) pigs were randomly assigned into 152 
seven groups of three pigs each, including two positive control groups (PCV1 and PRRSV), a 153 
negative control (MEM-treated group), and four groups for each of the PCV1-PRRSVEPI 154 
chimeric viruses. Pigs in each of the PCV1-PRRSVEPI chimeric virus groups and the PCV1-155 
positive control group were intramuscularly inoculated with 5 mL (4.64 × 102 TCDI50/mL) of the 156 
respective viruses. Pigs in the PRRSV-VR2385-positive control group were each inoculated 157 
with 5 mL (2 × 105 TCDI50/mL) of PRRSV-VR2385. Serum samples were collected from each 158 
pig prior to inoculation and weekly thereafter for a period of 7 weeks. 159 
 160 
8	  
	  
2.3.2. Quantification of viral DNA loads in sera and lung tissues 161 
The viral DNA was extracted from serum samples at 0, 7, 14, 21, 28, 35, and 42 days 162 
post-inoculation (dpi) and from tissues (lung and tracheobronchial lymph node) at 42 dpi, using 163 
Ambion MagMAX-96 Viral DNA Isolation kit (Thermo Fisher Scientific) according to the 164 
manufacturer’s instructions. The DNA standards used for the qPCR were virus stock used for 165 
inoculation as well as plasmids containing the full-length PCV1 infectious clone. In order to rule 166 
out potential cross-contamination, DNA extracted from PCV2a and PCV2b virus stocks, and 167 
empty pCR2.1TOPO vector (Invitrogen), were included as the negative control. The PCV1 DNA 168 
copy numbers in sera or tissues were quantified by a TaqMan® Fast Virus 1-Step Master Mix 169 
(Life Technologies Corp.) according to the manufacturer’s protocol. The PCR primers and 170 
probes (PCV1 P9/PCV1 P10/PCV1 probe) (Table 1) used in the qPCR assay were designed to 171 
target a specific amplicon of 97 bp in ORF2. The qPCR assay was conducted using the ABI 7500 172 
(RT) PCR system (Life Technologies Corp). The PCR conditions included denaturation at 95°C 173 
for 20 s, annealing at 95°C for 3 s, amplification at 60°C for 30 s, and a final extension at 72°C 174 
for 5 min, with a total number of 40 cycles. Each reaction was performed in triplicate. 175 
 176 
2.3.3. Serological evaluation of anti-PCV1 antibodies and anti-PRRSEPI antibodies: 177 
Specific antibodies against PCV1-Cap were tested by an indirect immunofluorescence 178 
assay (IIFA). For the IIFA, the PCV1-free PK-15 cells were inoculated with 100 µL of PCV1 179 
and incubated for 72 h at 37°C, and fixed in 80% acetone. Sera from pigs in each of the chimeric 180 
PCV1-PRRSVEPI-infected groups as well as from pigs in both the positive and negative control 181 
groups were serially diluted and incubated for 1 h at 37°C. Cells were washed three times with 182 
PBS, followed by addition of 100 µL (1:100) of fluorescent-labeled secondary anti-swine IgG 183 
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antibody (KPL, Kirkegaard & Perry Laboratories, Inc.). The cells were then washed again, and 184 
positive cells were detected using a fluorescence microscope. The virus titer was defined as the 185 
highest positive dilution and expressed as a mean geometric titer. The anti-PRRSV N antibody 186 
response was also evaluated using the IDEXX HerdCheck X3 ELISA kit according to the 187 
manufacturer’s instructions. 188 
Four different PRRSV KLH-conjugated synthetic antigenic peptides (GP2 epitope II: aa 189 
40–51, ASPSHVGWWSFA; GP3 epitope I: aa 61–72, QAAAEAYEPGRS; GP5 epitope I: aa 190 
35–46, SSSNLQLIYNLT; and GP5 epitope IV: aa 187–200, TPVTRVSAEQWGRP) were used 191 
as the antigen for the four PRRSV peptide-based antibody ELISAs. Each vial of lyophilized 192 
peptide (5 mg) was resuspended in 1 mL of UltraPure™ Distilled Water (Gibco®, Life 193 
Technologies) to a final stock concentration of 5 mg/mL, aliquotted, and stored at –80°C. 194 
Following titration and optimal dilution, 96-well microtitration plates (Nunc, Thermo Fisher 195 
Scientific) were manually coated with 100 µL per well of each peptide at a concentration of 5 196 
µg/mL in phosphate-buffered saline (PBS) at pH 7.4 (Gibco®, Life Technologies) and incubated 197 
at 4°C overnight. The ELISA conditions, including coating and blocking, buffers, sample and 198 
conjugate dilutions, and incubation conditions (time and temperature), were identical for the four 199 
different peptide-based ELISAs. Serum samples were diluted at 1:50, after which plates were 200 
loaded with 100 µL of the diluted sample per well. Plates were incubated at 37°C for 1 h and 201 
washed five times with PBS containing 0.1% Tween 20. Subsequently, 100 µL of peroxidase-202 
conjugated goat anti-pig IgG (Fc) antibody (Bethyl Laboratories Inc.), diluted at 1:15,000, were 203 
added to each well and the plates were incubated at 37°C for 1 h. After a washing step, the 204 
reaction was visualized by adding 100 µL of tetramethylbenzidine-hydrogen peroxide (Dako 205 
North America, Inc.) substrate solution to each well. After 10 min incubation at room 206 
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temperature, the reaction was stopped by the addition of 50 µL of a stop solution (1 M sulfuric 207 
acid) to each well. Reactions were measured according to the optical density at 450 nm using an 208 
ELISA plate reader (Biotek® Instruments Inc.) operated with commercial software (GEN5TM, 209 
Biotek® Instruments Inc.).  210 
 211 
2.3.4. Serum virus neutralization assay to evaluate the neutralizing activity against 212 
PRRSV VR2385: 213 
The neutralizing antibody titers against PRRSV-VR2385 were determined by a serum 214 
virus neutralization assay essentially as previously described (Zhou et al., 2012). Briefly, two-215 
fold diluted serum samples collected at 28, 35, and 42 dpi from each pig were mixed with an 216 
equal volume of the PRRSV VR2385 virus at an infectious titer of 2 × 103 TCID50/mL and 217 
incubated at 37°C for 1 h. The mixtures were then inoculated onto MARC-145 cells in 96-well 218 
plates and incubated for 1 h at 37°C. After washing with PBS, the cells were maintained in 219 
DMEM with 2% FBS. At approximately 20 hpi, the cells were assayed by IFA for virus 220 
infection. The neutralizing antibody titers were expressed as the highest dilution that showed a 221 
90% or above reduction in the number of fluorescent foci compared to that of antisera from 222 
negative control pigs. Samples were evaluated in triplicate and three independent tests were 223 
performed for each serum sample. 224 
 225 
2.4. Statistical analysis 226 
The Student’s t-test (unpaired) was used to evaluate the differences (P <0.05) between the 227 
samples in the two groups. Repeated measure two-way ANOVA with Tukey’s correction was 228 
calculated for multiple comparison. Statistical significance was set to alpha = 0.05. All analyses 229 
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were performed using commercially available software GraphPad Prism® 6 (GraphPad 230 
Software, Inc, CA).  231 
 232 
3. Results 233 
3.1. Chimeric PCV1 viruses containing PRRSV VR2385 antigenic epitopes inserted in 234 
the C-terminus of the PCV1 capsid are infectious in vitro: 235 
Each of the chimeric PCV1-PRRSEPI clones was verified by full-length genomic 236 
sequencing for the presence in frame of each of the inserted PRRSV antigenic epitopes in the C-237 
terminus of the PCV1 capsid gene. Transfection of each full-length chimeric virus DNA clone in 238 
PK-15 cells resulted in the production of infectious virions. Confocal microscopy revealed that 239 
each of the PCV1-PRRSEPI chimeric viruses expressed PCV1 Cap as well as the respective 240 
PRRSV antigenic determinant (Fig. 2). Infected cells showed dual nuclear staining with both 241 
anti-PCV1 monoclonal antibodies and anti-PRRSV epitope peptides (GP2 II, GP3I, GP5I, and 242 
GP5IV) mono-specific antibodies. There was no significant difference in the genomic copy 243 
numbers between wild-type PCV1 and PCV1-PRRSEPI chimeric viruses at 96 hpi (data not 244 
shown). The stability of chimeric viruses was confirmed after five successful serial passages in 245 
PK-15 followed by dual IFA staining of the PCV1 capsid and respective PRRSV antigenic 246 
determinant, as well as by sequence confirmation of the chimeric viruses harvested after the five 247 
passages (data not shown). 248 
3.2. PCV1-VR2385EPI chimeric viruses are viremic and replicate in tissues of 249 
experimentally inoculated pigs: 250 
All serum samples, evaluated by TaqMan® qPCR for the presence of PCV1 prior to 251 
inoculation at day 0, were negative. Viremia was detected at as early as 7 dpi for PCV1-252 
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VR2385EPIGP3I and PCV1-VR2385EPIGP5IV viruses, and at 21 dpi for PCV1-VR2385EPIGP2II 253 
and PCV1-VR2385EPIGP5I viruses (Table 2). The frequency of pigs showing viremia in each 254 
group varied during the trial. The number of animals used and the frequency variability do not 255 
allow for robust statistical analysis; however, the average DNA viral loads in serum samples 256 
from each chimeric virus were within one log10 difference: 1.39 × 105 genomic copies/mL for 257 
PCV1-VR2385EPIGP2II; 1.87 × 105 genomic copies/mL for PCV1-VR2385EPIGP3I; 4.22 × 105 258 
genomic copies/mL for PCV1-VR2385EPIGP5I; and 1.96 × 105 genomic copies/mL for PCV1-259 
VR2385EPIGP5IV, and had at least two-log10 lower genomic copies/mL than the parental PCV1 260 
(1.26 × 107 genomic copies/mL) (Fig. 3A). After 42 dpi, all animals were necropsied and no 261 
significant pathological lesions were observed. However, all infected groups had detectable viral 262 
DNA in the tracheobronchial lymph nodes and lungs (Table 2), indicating virus replication in 263 
tissues. No significant differences in viral genomic copy number/gram of tissue were observed 264 
between parental PCV1 and PCV1-VR2385EPI chimeric viruses in tracheobronchial lymph nodes 265 
and lungs (Fig. 3B). No evidence of PCV1 replication was observed in the PRRSV-VR2385 and 266 
MEM control groups.  267 
 268 
3.3. PCV1-VR2385EPI chimeric viruses induce both PCV1-specific and PRRSV antigenic 269 
epitope-specific antibodies in pigs: 270 
Anti-PCV1 IgG antibodies were detected in the sera of the wild-type PCV1 control group 271 
as well as all the PCV1-VR2385EPI chimeric viruses-inoculated groups. IgG anti-PCV1 272 
antibodies were detected from 14 dpi in wild-type PCV1-infected pigs and remained seropositive 273 
at 42 dpi. Anti-PCV1 IgG antibodies were detected in PCV1-VR2385EPIGP3I- and PCV1-274 
VR2385EPIGP5IV-infected groups at 14, 21, and 28 dpi, followed by a significant titer reduction 275 
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compared to the wild-type PCV1 at 35 and 42 dpi. The remaining chimeric viruses-infected 276 
groups, PCV1-VR2385EPIGP2II and PCV1-VR2385EPIGP5I, showed a delayed seroconversion to 277 
anti-PCV1 IgG antibodies (35 dpi) and significantly lower levels of anti-PCV1 IgG antibodies, 278 
compared to the wild-type PCV1-infected group, at 35 and 42 dpi (Fig. 4A). Anti-PCV1 IgG 279 
antibodies were not detected in PRRSV or MEM control groups. As expected, anti-PRRSV N 280 
antibodies were only detected in the PRRSV 2385 infected group (Fig. 4B).  281 
 Antibody responses against the inserted PRRSV antigenic epitopes were detected by 282 
specific epitope-based ELISA. Antibody response against PRRSV-GP2 epitope II was not 283 
detected in pigs experimentally infected with the PCV1-VR2385EPIGP2II chimeric virus (Fig. 284 
5A). However, specific antibodies against PRRSV-GP3 epitope I were detected in the PCV1-285 
VR2385EPIGP3I chimeric virus group at 28 dpi and remained positive at 42 dpi (Fig. 5B). 286 
Specific antibodies against PRRSV-GP5 epitope I were detected at 21 dpi in the wild-type 287 
PRRSV VR2385-infected group, and at 35 dpi in the PCV1-VR2385EPIGP5I chimeric virus-288 
infected group at 35 dpi, and remained positive at 42 dpi (Fig. 5C). The presence of anti-289 
PRRSV-GP5 epitope IV antibodies was detected at 21 dpi in the PCV1-VR2385EPIGP5IV 290 
chimeric virus group and at 28 dpi in wild-type PRRSV VR2385 group, and remained at a high 291 
level in the PCV1-VR2385EPIGP5IV chimeric virus group at 35 and 42 dpi (Fig. 5D). The low 292 
number of animals per group, as well as individual variation amongst animals may play a role in 293 
the different levels of antibodies response observed amongst groups.  294 
 295 
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3.4. PCV1-PRRSVEPI chimeric viruses-infected pigs develop neutralizing antibodies 296 
against the PRRSV VR2385:  297 
To investigate whether PCV1-VR2385EPI chimeric viruses can induce neutralizing 298 
antibodies against PRRSV, a serum virus neutralization assay against PRRSV VR2385 strain 299 
was performed. Anti-PRRSV-VR2385 neutralizing antibodies were detected in the PCV1-300 
VR2385EPIGP3I, PCV1-VR2385EPIGP5I, and PCV1-VR2385EPIGP5IV chimeric viruses-infected 301 
groups at 28 dpi and remained detectable at 42 dpi. No statistical difference in neutralizing 302 
antibody titers were observed throughout the experiment between wild-type PRRSV VR2385 303 
and PCV1-VR2385EPIGP3I, PCV1-VR2385EPIGP5I, and PCV1-VR2385EPIGP5IV, except for 304 
PCV1-VR2385EPIGP5I at 42 dpi (Fig. 6). PRRSV 2385 neutralizing antibodies were not detected 305 
in PCV1 or MEM control groups.  306 
 307 
4. Discussion 308 
PCV1 is a non-pathogenic virus in pigs infecting multiple tissues and organs (Allan et al., 309 
1995; Calsamiglia et al., 2002; Krakowka et al., 2000). Early field studies reported a high 310 
serological prevalence of anti-PCV1 antibodies in the swine population (Dulac and Afshar, 1989; 311 
Edwards and Sands, 1994; Tischer et al., 1995), although no disease could be associated with the 312 
presence of this virus either naturally or experimentally (Allan et al., 1995; Tischer et al., 1986). 313 
However, more recent field studies have demonstrated that the serological prevalence of anti-314 
PCV1 antibodies as well as virus circulation in the swine population are very low (Puvanendiran 315 
et al., 2011). Sequence and phylogenetic analyses have also demonstrated a low mutation rate 316 
and low genetic diversity of the PCV1 strains worldwide (Tombácz et al., 2014). Thus, the low 317 
prevalence of PCV1, lack of evidence of pathogenicity, low mutation rate, and systemic tropisms 318 
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for multiple tissues and organs make PCV1 an attractive candidate for a potential live vaccine 319 
vector. 320 
Previous studies have successfully used the non-pathogenic PCV1 as the genomic 321 
backbone for the development of PCV2 vaccines (Fenaux et al., 2004). Cloning of PCV2 ORF2 322 
capsid gene into the backbone of PCV1 proved to be viable in vivo and conferred full protection 323 
against PCV2, whilst still retaining the non-pathogenic nature of PCV1 (Fenaux et al., 2004; 324 
Fenaux et al., 2003). Additionally, pigs experimentally infected with a PCV2-1 reciprocal 325 
chimeric virus, containing PCV1 ORF2 in a PCV2 backbone, showed specific anti-PCV1 IgG 326 
antibody response (Fenaux et al., 2003). Herein in this study, we further demonstrated that 327 
insertion of known PRRSV antigenic determinants in the C-terminus of PCV1 ORF2 capsid gene 328 
produced infectious chimeric viruses and did not impair the humoral immune response against 329 
PCV1. Although different levels of anti-PCV1 IgG were detected, all PCV1-VR2385EPI chimeric 330 
viruses were capable of induce anti-PCV1 IgG antibodies in infected SPF pigs.  331 
The different levels of anti-PCV1 IgG antibodies might be associated with a different 332 
replication timeline and viral DNA load observed amongst the various PCV1-VR2385EPI 333 
chimeric viruses compared with wild-type PCV1. The extension of the C-terminus of the PCV1 334 
capsid gene through the addition of PRRSV antigenic epitopes might also affect the structural 335 
conformation and antibody induction capability of the PCV1 capsid. Indeed, previous studies 336 
demonstrated that mutation of the last four amino acid residues of the PCV2 ORF2 (-PLKP) to 337 
three amino acid residues of the PCV1 ORF2 (-LNK) reduces viral antibody recognition 338 
(Lekcharoensuk et al., 2004). Therefore, in the current study, anti-PCV1 IgG antibodies 339 
generated against PCV1-VR2385EPI chimeric viruses may not completely bind to the full PCV1 340 
Cap expressed by the wild-type PCV1 that was used for the IIFA serology test. Further studies 341 
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will be necessary to demonstrate whether the insertion of a foreign amino acid sequence at the C-342 
terminus may alter the conformation of the PCV1 capsid protein. 343 
It has been previously demonstrated that the C-terminus of the PCV2 capsid is a type-344 
specific immune reactive epitope that is displayed on the surface of the virion capsid 345 
(Lekcharoensuk et al., 2004; Shang et al., 2009). In two separate studies, following the insertion 346 
of epitope tags in the C-terminal region, PCV2 and chimeric PCV1-2a vaccine were generated 347 
and shown to elicit dual immunity against both PCV2 capsid and the inserted epitopes, whereas 348 
mutation of the N-terminus of PCV2 capsid impaired viral replication (Beach et al., 2011; 349 
Pineyro et al., 2015). Herein in the present study, we inserted four different known PRRSV 350 
antigenic epitopes into the C-terminus of the non-pathogenic PCV1 capsid gene, and 351 
demonstrated that the insertions did not significantly affect virus infectivity in vitro or viral 352 
replication in vivo. We previously showed that epitopes as large as 27 amino acids can be 353 
inserted in the PCV2 capsid gene without impairing viral viability (Beach et al., 2011). In the 354 
present study, we demonstrated that insertions, varying from 12 aa for PRRSV-GP3 epitope I 355 
and PRRSV-GP5 epitope I, 12 aa for PRRSV-GP2 epitope II, and 14 aa for PRRSV-GP5 epitope 356 
IV, did not affect viral infectivity in vitro or replication in vivo. Future study is necessary to 357 
determine the tolerance of maximal length of amino acid insertion in PCV1 capsid without 358 
affecting the viability of the virus.  359 
Although the PCV1 chimeric viruses generated in this study were capable of replicating 360 
in vivo, the rate of replication appears to be low. It has previously been demonstrated that PCV1 361 
can replicate to a higher titer in vitro, compared to PCV2 (Beach et al., 2010a). However, to our 362 
knowledge, there is no information regarding the minimal infectious dose required for PCV1 363 
infection in vivo. Previous studies using PCV1-2 chimeric virus in the backbone of PCV1 364 
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showed positive results with variable titers (Beach et al., 2010b; Fenaux et al., 2004; Pineyro et 365 
al., 2015). We therefore speculate that the low replication rate of the chimeric viruses observed 366 
in this study might be due to a low virus titer that was used for inoculation. Propagation of 367 
PCV1, PCV2 as well as chimeric viruses to higher infectious titers have been very challenging 368 
thus far. 369 
 In the current study, PCV1 chimeric viruses expressing four known B-cell linear epitopes 370 
of PRRSV, previously demonstrated to be immunogenic against PRRSV (de Lima et al., 2006; 371 
Plagemann, 2004b; Vanhee et al., 2011), were generated. It has been reported that GP5 plays a 372 
major role in PRRSV neutralization (Plagemann, 2004a; Plagemann, 2004b; Plagemann et al., 373 
2002). PRRSV-GP5 epitope IV is an important immunogenic epitope (P188LTR (V/T) 374 
SAEQW197) that has also been proved to be reactive with sera raised against European PRRSV 375 
strains. Despite a few amino acid changes, this epitope seems to be well conserved amongst type 376 
2 PRRSV strains (Oleksiewicz et al., 2001). We showed in this study that PCV1-377 
VR2385EPIGP5IV chimeric virus induced neutralizing antibody levels comparable to those 378 
induced by the PRRSV VR2385 virus. The PRRSV-GP5 epitope I neutralizing epitope, 379 
37SHLQLIYNL, for the PRRSV VR2332 is located in the GP5 ectodomain sequence and is 380 
considered as the primary neutralizing epitope for the type 2 PRRSV isolates (Plagemann, 381 
2004b). The PCV1-VR2385EPIGP5I chimeric virus in this study induced similar neutralizing 382 
antibody levels compared to those induced by PRRSV VR2385 virus at 28, and 35 dpi. However, 383 
the neutralizing antibody titers induced by the PCV1-PRRSVEPI viruses appeared to decline more 384 
rapidly compared to the PRRSV VR2385, thus causing a significant reduction of neutralizing 385 
antibodies titer at 42 dpi.  386 
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PRRSV ORF3 is considered as the second most variable PRRSV structural protein, with 387 
four consecutive peptides from aa 61–105, all of which are considered as important 388 
immunodominant domains of GP3 (de Lima et al., 2006; Zhou et al., 2006).  The PCV1-389 
VR2385EPIGP3I chimeric virus generated in this study contains the aa 61–72 390 
(QAAAEAYEPGRS) and was shown to induce similar levels of neutralizing antibodies 391 
compared to the PRRSV VR2385. Despite the fact that PCV1-VR2385EPIGP2II chimeric virus 392 
is infectious in vitro, no viral DNA were detected in tissues of inoculated pigs, probably due to 393 
the short duration of viremia not being detectable with the current sampling scheme. This 394 
explanation was also supported by the presence of anti-PCV1 IgG at 14 dpi, indicative of virus 395 
replication. Furthermore, the chimeric virus also failed to induce antibodies against PRRSV-GP2 396 
epitope II. Therefore, we have successfully demonstrated that three of the four PCV1-VR2385EPI 397 
chimeric viruses generated in this study induced PRRSV epitope-specific antibodies and 398 
neutralizing antibodies against PRRSV VR2385 at a level comparable to those induced by wild-399 
type PRRSV VR2385.  400 
In summary, we successfully generated and rescued four PCV1 chimeric viruses 401 
expressing different known PRRSV linear-B epitopes (GP2 epitope II: aa 40–51, 402 
ASPSHVGWWSFA; GP3 epitope I: aa 61–72, QAAAEAYEPGRS; GP5 epitope I: aa 35–46, 403 
SSSNLQLIYNLT; and GP5 epitope IV: aa 187–200, TPVTRVSAEQWGRP). We further 404 
showed that three of these chimeric viruses were infectious in vitro and in pigs, and genetically 405 
stable. Importantly, we found that three PCV1-VR2385EPI chimeric viruses elicited neutralizing 406 
antibodies against PRRSV-VR2385. Therefore, the results from the present study provided a 407 
proof of concept for further exploring the use of the non-pathogenic PCV1 as a live virus vector 408 
for vaccine delivery. 409 
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Figure legends 568 
Fig. 1. A schematic diagram for the construction of the PCV1-PRRSVEPI chimeric DNA 569 
clones. The epitope insertion was accomplished by two rounds of overlapping extension PCR. 570 
The first amplicon of 200 bp containing an overhanging GPxxEPI region (xx denote different 571 
inserted epitopes, GP2II, G3I, GP5I and GP5IV) was generated with M13-F and GPxxEPI-R 572 
primers (black arrows). The second amplicon of 1778 bp containing a complementary GPxxEPI 573 
overhanging region was generated with GPxxEPI-F and M13-R primers (empty arrow heads). The 574 
full-length PCV1-PRRSV epitopes chimeric clones were assembled by a fusion PCR using 575 
previously generated amplicons as templates, and with M13-F and M13-R primers.  576 
 577 
Fig. 2. Confocal microscopy of PK-15 cells infected with wild-type PCV1 as well as with 578 
four different PCV1-PRRSVEPI chimeric viruses. PCV1-PRRSVEPI chimeric viruses (PCV1-579 
VR2385EPIGP2II, PCV1-VR2385EPIGP3I, PCV1-VR2385EPIGP5I, and PCV1-VR2385EPIGP5IV) 580 
and wild-type PCV1 were assayed by dual immunofluorescence staining. Infected cells were 581 
dually labeled with a mixture of mouse anti-PCV1 capsid monoclonal antibody (1:1000) (Mab) 582 
and PRRSV epitope-specific polyclonal antibodies (1:500) (Pab). In order to determine cross 583 
reactivity, cells infected with each specific chimeric virus group were tested against each 584 
respective PRRSV-specific epitope antibody. After incubation with the primary antibody, a 585 
mixture of fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG (1:100) (KPL, 586 
Kirkegaard & Perry Laboratories, Inc.) and goat anti-rabbit IgG-DyLight (1:500) (Thermo 587 
Scientific) were added. Dually infected cells were visualized using a Zeiss LSM 880 confocal 588 
microscope (Zeiss, Pleasanton, CA) with a 40X objective, using the argon 488 and helium-neon 589 
594 lasers. 590 
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Fig. 3. Detection and quantification of PCV1 viral DNA loads in serum, lymphoid tissues 591 
and lung samples in specific-pathogen-free (SPF) pigs experimentally infected with PCV1-592 
PRRSVEPI chimeric viruses. Pigs were experimentally infected with wild-type PCV1 as well as 593 
each of the four different PCV1-PRRSVEPI chimeric viruses (PCV1-VR2385EPIGP2II, PCV1-594 
VR2385EPIGP3I, PCV1-VR2385EPIGP5I, and PCV1-VR2385EPIGP5IV). Determination of viral 595 
DNA loads in serum and tissues was performed using TaqMan® qPCR. The number of animals 596 
used and the frequency variability in each time point, do not allow for robust statistical analysis. 597 
(A) Group mean log viral genomic copies/ml of serum is plotted for each treatment group, and 598 
the error bars indicate standard errors. (B) Mean viral DNA loads in tracheobronchial lymph 599 
node and lung were determined for each treatment group. Mean log viral genomic copies/gram 600 
of tissue is plotted for each treatment group, and the error bars indicate standard errors.  601 
 602 
Fig. 4. Anti-PCV1 IgG antibodies and anti-PRRSV N antibodies in specific-pathogen-free 603 
(SPF) pigs experimentally infected with PCV1-PRRSVEPI chimeric viruses. Pigs were 604 
infected with wild-type PCV1 as well as with each of the four different PCV1-PRRSVEPI 605 
chimeric viruses. (A) Anti-PCV1 IgG antibodies were detected by an indirect 606 
immunofluorescence assay (IIFA). PCV1-free PK15 cells were infected with 1 MOI of wild-type 607 
PCV1. Immunoreactivity against PCV1 was evaluated in serum samples generated in pigs 608 
infected by wild-type PCV1, PCV1-PRRSVEPI chimeric viruses, PRRSV-VR2385 and MEM 609 
control.  Detectable anti-PCV1 IgG antibodies were seen as early as 14 dpi in wild-type PCV1, 610 
PCV1-VR2385EPIGP3I, and PCV1-VR2385EPIGP5IV, followed by PCV1-VR2385EPIGP2II, and 611 
PCV1-VR2385EPIGP5I at 21 dpi. Treatments with different letters represent statistically 612 
significant differences on that day. (B) The anti-PRRSV N antibody titers at indicated time 613 
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points were detected using the IDEXX HerdCheck X3 ELISA kit. The level of antibody was 614 
expressed as a sample/positive (S/P) value ratio. The dash line shows the cutoff threshold (S/P 615 
value ≥0.4). Each plot represents the mean value of 3 pigs per infected group at each time point. 616 
Statistical comparison was performed using repeated-measures analysis of variance, followed by 617 
Tukey’s post-hoc procedure for multiple comparisons. Statistical significance was set to alpha = 618 
0.05.  619 
 620 
Fig. 5. PRRSV antigenic epitope-specific ELISAs for detection of the inserted PRRSV 621 
epitope antibodies induced by PCV1-PRRSVEPI chimeric viruses. Specific-pathogen-free 622 
pigs were infected with wild-type PCV1, as well as with each of the four PCV1-PRRSVEPI 623 
chimeric viruses containing respective PRRSV antigenic epitopes. PRRSV epitope-specific 624 
antibody responses were tested in serum samples of pigs infected with PCV1-VR2385EPIGP2II, 625 
PCV1-VR2385EPIGP3I, PCV1-VR2385EPIGP5I, and PCV1-VR2385EPIGP5IV, wild-type PCV1, 626 
and PRRSV VR2385. All infected groups were tested individually against each epitope peptide. 627 
(A) PCV1-VR2385EPIGP2II; (B) PCV1-VR2385EPIGP3I; (C) PCV1-VR2385EPIGP5I; and (D) 628 
PCV1-VR2385EPIGP5IV. The average of three animals is plotted for each time point, and 629 
standard errors are indicated. Asterisks indicate significant differences on that day for each of the 630 
PCV1-PRRSVEPI chimeric viruses compared to PRRSV VR2385 infected group. The dotted 631 
horizontal line indicates the cutoff of each assay. Statistical comparison was performed using 632 
two-way ANOVA followed Tukey’s correction for multiple comparison. Statistical significance 633 
was set to alpha = 0.05.  634 
 635 
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Fig. 6. Kinetics of anti-PRRSV neutralizing antibody response in pigs experimentally 636 
infected with each of the four PCV1-VR2385EPI chimeric viruses as well as with the PRRSV 637 
VR2385 virus. Neutralizing antibody (NA) titers induced against the PRRSV VR2385 by each 638 
of the four PCV1-VR2385EPI chimeric viruses as well as by the parental PRRSV VR2385 virus 639 
were detected as early as 28 dpi. NA antibodies titers observed in the PCV1-VR2385EPIGP3I, 640 
PCV1-VR2385EPIGP5I, and PCV1-VR2385EPIGP5IV groups against PRRSV VR2385 were 641 
comparable to those observed in the PRRSV VR2385-infected group at 28 and 35 dpi.  At 42 642 
dpi, the NA antibodies titers in PCV1-VR2385EPIGP5IV group were significantly lower than 643 
those observed in the PRRSV-VR2385-infected group. The NA titers against parental strain 644 
PRRSV VR2385 and each of the PCV1-VR2385EPI chimeric viruses were expressed as the 645 
highest dilution (2n) that showed a 90% or above reduction in the number of fluorescent foci 646 
compared to that of serum from negative control group. The NA titers against PCV1-VR2385EPI 647 
GP2 II was not shown because of undetectable NA titer.  Three independent experiments were 648 
performed for each test, and the error bars indicate standard errors. The P value shows whether 649 
one chimeric virus group had significant differences in NA titers compared to the parental 650 
PRRSV VR2385 group. 651 
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Table 1.	  Primer sequences used in the construction and detection of the PCV1-PRRSVEPI chimeric 1 
viruses 2 
Chimeric clone  Primer  Position  Primer sequence (5’-3’) 
PCV1-PRRSVEPIGP2II GP2IIEPI-P1 F47-59 CGCAAAGCTCCACCAGCCCACATGGCTCGGGCTCGCag
ggtcttttagg 
 GP2IIEPI-P2 R29-46 GCGAGCCCGAGCCATGTGGGCTGGTGGAGCTTTGCGcta
aatgaataaaaataa 
PCV1-PRRSVEPIGP3I GP3IEPI-P3 F47-59 GCTACGGCCCGGTTCATACGCTTCCGCCGCCGCCTGagg
gtcttttagg 
 GP3IEPI-P4 R29-46 CAGGCGGCGGCGGAAGCGTATGAACCGGGCCGTAGCct
aaatgaataaaaataa 
PCV1-PRRSVEPIGP5I GP5IEPI-P5 F47-59 GGTCAGGTTATAAATCAGCTGCAGGTTGCTGCTGCTagg
gtcttttagg 
 GP5IEPI-P6 R29-46 AGCAGCAGCAACCTGCAGCTGATTTATAACCTGACCcta
aatgaataaaaataa  
PCV1-PRRSVEPIGP5IV GP5IVEPI-P7 F47-59 CGGACGGCCCCACTGTTCCGCGCTCACACGGGTCACC
GGGGTagggtcttttagg 
 GP5IVEPI-P8 R29-46 ACCCCGGTGACCCGTGTGAGCGCGGAACAGTGGGGCC
GTCCG ctaaatgaataaaaataa 
pCR2.1 TOPO M13-R R207-225 GGAAACAGCTATGACCATG 
pCR2.1 TOPO M13-F F390-406 ACTGGCCGTCGTTTTAC 
PCV1  P9 F505-525 CGATGTTGAATCTGAGGTGGT 
PCV1 P10 R581-602 AGAAAGGCGGGAATTGAAGATA 
PCV1  Probe R528-553 ACATTCCAAGATGGCTGCGAGTATCC 
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Table 2. Detection of viremia and virus replication in tissues of pigs infected by parental PCV1, and 4 
each of the four PCV1-PRRSVEPI chimeric viruses 5 
Treatments	  
No. of pigs with detectable viremia and viral genome in tissues  
(positive/total no. of pigs)	  
   dpi       
0 7 14 21 28 35 42 Total Lung TBLN 
PCV1-VR2385
EPI
GP2II 0/3 0/3 0/3 1/3 2/3 2/3 0/3 2/3 1/3 1/3 
PCV1-VR2385
EPI
GP3 I 0/3 1/3 0/3 0/3 1/3 0/3 0/3 2/3 1/3 1/3 
PCV1-VR2385
EPI
GP5 I 0/3 0/3 0/3 2/3 1/3 3/3 1/3 3/3 1/3 2/3 
PCV1-VR2385
EPI
GP5IV 0/3 1/3 1/3 0/3 1/3 1/3 0/3 2/3 3/3 2/3 
PCV1 0/3 2/3 1/3 1/3 1/3 1/3 2/3 2/3 2/3 2/3 
PRRSV-VR2385 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 
Mock (MEM) 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 
dpi: days post infection, TBLN tracheobronchial lymph nodes 6 
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